Precision medicine is expanding into psychiatry, as new tests emerge to detect the underlying genetic or physiological causes of disorders in specific individuals and companion diagnostics are developed to guide the selection of therapeutics.
Depression affects approximately 17 million adults in the U.S. nearly 7% of the U.S. population, according to the National Institute of Mental Health. Yet, until quite recently, new treatment approaches were one-size-fits-all. Prozac (fluoxetine), a selective serotonin reuptake inhibitor (SSRI), is the poster child. Such treatments were developed for large populations of depressed individuals, but they dont work for everyone, Hans Eriksson,M.D., Ph.D., chief clinical development officer at HMNC Brain Health, told BioSpace.
As a clinical psychiatrist, I was struck by the fact that depressed patients have many different manifestations. Some may be sad, have low energy and eat and sleep a lot, while others with the same condition may be irritable, agitated, eat less and wake up early. It was a struggle to understand whether the same biology was at work. Until recently, we lacked tools (to do that), Eriksson said.
Now, he continued, with advances in genetic analyses and artificial intelligence, science is on the brink of developing psychiatry into a much more sophisticated scientific discipline. That implies the combination of novel and repurposed interventions with precision applications.
For example, about 30% of depressed patients seem to have a hyperactive stress response system that isnt controlled the normal way, Eriksson said. Some patients with chronic depression could, therefore, be treated with a vasopressin V1b antagonist to control the central overactivity in the brain that triggers the production of a stress hormone.
Scientists working with HMNC Brain Health have tested the hyperactive stress response in individuals and mapped it to genetics, which yielded a relevant set of single nucleotide polymorphisms (SNPs). Consequently, the company has the genetic signature of individuals with a tendency toward hyperactive stress response systems the V1b test.
HMNC Brain Health subsidiary, Nelivabon, is in-licensing a V1b antagonist (BH-200) that, with the companion V1b test, has the potential to improve outcomes by targeting the patient population best able to benefit from this intervention.
The V1b antagonist was in phase II trials at Sanofi a decade ago, and demonstrated efficacy, Eriksson said. Although it showed statistical significance, it would have competed with generics and was not developed further. Our belief is that its efficacy was driven by a subset of individuals with hyperactive stress systems. So, with the V1b test, we expect to see superior efficacy in this population.
Eriksson said that HMNC Brain Health is a pioneer in developing precision medicine for the psychiatric space. Its possible because of increasing knowledge in neuroscience, the availability of cost-effective genetics analysis and the increasing maturation of artificial intelligence.
AI has simplified things. We can do broad genetic analyses of populations and AI can help us find genetic signatures that may not be evident otherwise. Then we can test to verify that the findings are meaningful, he stated.
As more is learned about the brain, scientists are also exploring drugs with new mechanisms of action and modifications of drugs of abuse, such as psilocybin and ecstasy, to develop appropriate, controlled treatments.
Ketamine is a good example. It has been used as an anesthetic for more than 50 years and some researchers are showing that it also has an antidepressant effect. Unfortunately, in about a quarter of patients, its side-effects include dissociative experiences (such as hallucinations) and increased blood pressure when delivered intranasally or intravenously. Therefore, the approved formulation of esketamine has to be administered under the supervision of a healthcare professional. That, however, leads to logistical issues in practical medicine, Eriksson pointed out.
HMNC Brain Health subsidiary, Ketabon, is developing an oral, extended-release formulation without those side-effects as a treatment for chronic depression. It has slow uptake, so lowers the risks, he said, which suggests it may be able to be taken by patients at home. A phase II study comparing this extended-release formulation administered in combination with traditional antidepressants, versus antidepressants alone, is underway at the Psychiatric Hospital of the University of Zurich.
HMNC Brain Health and its subsidiaries and partners are developing other trials for a variety of companion diagnostics, with several in or about to enter the clinic. Its ABCB1 gene variant test, which guides the selection of antidepressants, is already on the market in France, Germany and Switzerland.
We are in an era where repurposed and novel interventions are coming into this (psychiatric) space. As a clinician, Eriksson said, its promising to see growing access to differentiated treatments with different mechanisms of action.
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 21st, 2021
- Immunosuppressants linked to severe reactions in people with common genetic profile - Stanford Medical Center Report - November 21st, 2021
- A video that originated on InfoWars is filled with falsehoods about COVID-19 vaccines - PolitiFact - November 21st, 2021
- Gene signature may give an upper hand in metastatic breast cancer - Baylor College of Medicine News - November 21st, 2021
- Lung cancer management in the era of precision medicine - Express Healthcare - November 21st, 2021
- Powerful gene-based testing by integrating long-range chromatin interactions and knockoff genotypes - pnas.org - November 21st, 2021
- Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting - Business... - November 21st, 2021
- European Commission approves Roche's Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer |... - November 21st, 2021
- Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring - pnas.org - November 21st, 2021
- Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With... - November 21st, 2021
- Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled... - November 21st, 2021
- Gene Therapy and Genetic Engineering - MU School of Medicine - November 17th, 2021
- Gene editing: Great for medicine but ethical issues arise - November 17th, 2021
- Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders - FierceBiotech - November 17th, 2021
- gene therapy | Description, Uses, Examples, & Safety ... - November 17th, 2021
- Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development - Yahoo Finance - November 17th, 2021
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 17th, 2021
- 8 medical advances you may have missed during COVID-19 - AAMC - November 17th, 2021
- PNAS Papers on Woodrat Microbiome, Maternal Cannabis Use, Gene-Based Testing - GenomeWeb - November 17th, 2021
- Single Cell Multiomic Atlas of the Human Retina: An Integrative Analysis - Genetic Engineering & Biotechnology News - November 17th, 2021
- Map of Mouse Iris Offers New Look at the Eye - Howard Hughes Medical Institute - November 17th, 2021
- Is every gene associated with cancer? - Medical News Today - November 15th, 2021
- Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy - BioPharma Dive - November 15th, 2021
- A mammoth solution - Harvard Office of Technology Development - November 15th, 2021
- Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Franon PhD as Chief... - November 15th, 2021
- Cell and Gene Therapy Catapult and Deep Science Ventures collaborate to overcome barriers in ATMPs - BioPharma-Reporter.com - November 15th, 2021
- Regenerative Medicine Market to reach US$ 25,959.5 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 15th, 2021
- Dr Pengyi Yang wins National Stem Cell Foundation Metcalf Prize - News - The University of Sydney - November 15th, 2021
- Researchers make strides identifying genetic causes of rare neurodevelopmental disorders in the Turkish and worldwide populations - Baylor College of... - November 15th, 2021
- Saving the world with synthetic biology - Scope - Scope - November 15th, 2021
- GenSight Biologics to Present New Clinical Data of LUMEVOQ and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting - Business... - November 15th, 2021
- Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME - MD Magazine - November 15th, 2021
- Role of gene associated with Alzheimer's disease in brain's immune cells investigated by scientists - Devdiscourse - November 15th, 2021
- Attitudes among parents of persons with autism spectrum disorder towards information about genetic risk and future health | European Journal of Human... - November 15th, 2021
- Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED - PRNewswire - November 15th, 2021
- Arizona researchers have a Valley fever vaccine for dogs and that's good news for humans - KJZZ - November 15th, 2021
- Study revealed the function of mysterious structure found on neurons - Tech Explorist - November 15th, 2021
- New Research Helps Explain the Genetic Basis of Why We Look the Way We Do - UC San Diego Health - November 15th, 2021
- Gene Therapy Shows Early Promise as Angelman Syndrome Treatment | Newsroom - UNC Health and UNC School of Medicine - October 26th, 2021
- Report by Mott Center researchers named NIEHS Extramural Paper of the Month - The South End - October 26th, 2021
- Clinical Data from Editas Medicines Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene... - October 26th, 2021
- Delic Partners With GT Research for Genetic Analysis of Cannabis, Psychedelic Mushrooms - GenomeWeb - October 26th, 2021
- Alcyone Therapeutics Strengthens Executive Team with New Senior Leadership Appointments - WABI - October 26th, 2021
- The Genomic Revolution: Why Investors Are Paying Attention - Visual Capitalist - October 26th, 2021
- Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T in Advanced ROR1+ Hematological and Solid Tumors - WAGM - October 26th, 2021
- 5 Trends Shaping the Future of eCommerce - Visual Capitalist - October 26th, 2021
- Anatomy texts should show sex as a spectrum to include intersex people - The Conversation AU - October 26th, 2021
- Early Results of Gene Therapy for Angelman Syndrome Look Promising - AJMC.com Managed Markets Network - October 24th, 2021
- Ten Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune Disease - HealthDay News - October 24th, 2021
- Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit - Yahoo Finance - October 24th, 2021
- Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery... - October 24th, 2021
- ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit - WCAX - October 24th, 2021
- Lovelace Biomedical Presents a New Webinar on Rare Diseases and Gene Therapy Preclinical Research - PRNewswire - October 24th, 2021
- Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there? - FiercePharma - October 24th, 2021
- Senti Bio CEO Appointed to The Alliance for Regenerative Medicine 2022 Board of Directors - StreetInsider.com - October 24th, 2021
- ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs - MedCity News - October 24th, 2021
- From cancer to Crohn, Israel pushes precision medicine to the next level - The Jerusalem Post - October 24th, 2021
- Tulane scientists unravel 50-year-old medical mystery behind toddlers' deaths from RSV vaccine - Tulane News - October 24th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 24th, 2021
- Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy - Cystic Fibrosis News Today - October 24th, 2021
- LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using... - October 24th, 2021
- Global Pharmaceutical Contract Development and Manufacturing Markets, 2021-2026 - Increasing Demand for Biological & Cell and Gene Therapies /... - October 24th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - The Highland County Press - October 24th, 2021
- Hunterian Medicine Licenses Inscriptas MAD7 Nuclease to Advance Gene Editing Research and Development - Yahoo Finance - October 17th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 17th, 2021
- 4 Biotechs to Watch Amid Rising Prominence of Gene Therapies - Yahoo Finance - October 17th, 2021
- The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics - Yahoo Finance - October 17th, 2021
- Could an Old Drug Be a New Alzheimers Treatment? - AARP - October 17th, 2021
- 5 Slides: Gene therapy and the promise for rare disease - State of Reform - State of Reform - October 17th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 17th, 2021
- Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress - StreetInsider.com - October 17th, 2021
- Genetic screening test leads to discovery of a family trait - Sanford Health News - October 17th, 2021
- Filling the gaps: connecting genes to diseases through proteins - EurekAlert - October 17th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - GlobeNewswire - October 17th, 2021
- Polygenic screening of embryos is here, but is it ethical? - The Guardian - October 17th, 2021
- Wolter Earns Young Investigator Award | Newsroom - UNC Health and UNC School of Medicine - October 17th, 2021
- Patient Care on the Precipice of Transformation at Penn Medicine's New Pavilion - pennmedicine.org - October 17th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 11th, 2021
- CRISPR is revolutionizing medicine its origin story is pretty incredible, too - Freethink - October 11th, 2021
- Longevity Foundation to Fund Geroscience Research with 860M - Labiotech.eu - October 11th, 2021